Pfizer Inc Net Income
| PFE Stock | USD 26.10 0.24 0.93% |
As of the 30th of January, Pfizer holds the Risk Adjusted Performance of 0.0787, semi deviation of 1.14, and Coefficient Of Variation of 981.89. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pfizer, as well as the relationship between them. Please check Pfizer Inc information ratio, as well as the relationship between the value at risk and expected short fall to decide if Pfizer Inc is priced some-what accurately, providing market reflects its current price of 26.1 per share. Given that Pfizer has jensen alpha of 0.087, we recommend you to check out Pfizer Inc's recent market performance to make sure the company can sustain itself at a future point.
Pfizer Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.1302 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 9.3 B | 9.3 B | |
| Net Income Applicable To Common Shares | 9.2 B | 12.2 B | |
| Net Income From Continuing Ops | 9.3 B | 13.1 B | |
| Net Income Per Share | 1.27 | 0.94 | |
| Net Income Per E B T | 0.90 | 0.70 |
Pfizer | Net Income | Build AI portfolio with Pfizer Stock |
Analyzing Pfizer's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Pfizer's current valuation and future prospects.
Latest Pfizer's Net Income Growth Pattern
Below is the plot of the Net Income of Pfizer Inc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pfizer Inc financial statement analysis. It represents the amount of money remaining after all of Pfizer Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pfizer's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 8.05 B | 10 Years Trend |
|
Net Income |
| Timeline |
Pfizer Net Income Regression Statistics
| Arithmetic Mean | 11,325,279,456 | |
| Geometric Mean | 8,614,167,576 | |
| Coefficient Of Variation | 67.16 | |
| Mean Deviation | 5,425,012,085 | |
| Median | 9,159,000,000 | |
| Standard Deviation | 7,606,423,198 | |
| Sample Variance | 57857673.9T | |
| Range | 30.8B | |
| R-Value | 0.22 | |
| Mean Square Error | 58670107.8T | |
| R-Squared | 0.05 | |
| Significance | 0.39 | |
| Slope | 334,573,054 | |
| Total Sum of Squares | 925722781.9T |
Pfizer Net Income History
Other Fundumenentals of Pfizer Inc
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pfizer Net Income component correlations
Pfizer Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pfizer is extremely important. It helps to project a fair market value of Pfizer Stock properly, considering its historical fundamentals such as Net Income. Since Pfizer's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pfizer's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pfizer's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Pfizer diversify its offerings? Factors like these will boost the valuation of Pfizer. Anticipated expansion of Pfizer directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pfizer data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.21) | Dividend Share 1.7 | Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth (0.06) |
Investors evaluate Pfizer Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pfizer's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pfizer's market price to deviate significantly from intrinsic value.
It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pfizer's market price signifies the transaction level at which participants voluntarily complete trades.
Pfizer 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pfizer's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pfizer.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Pfizer on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Pfizer Inc or generate 0.0% return on investment in Pfizer over 90 days. Pfizer is related to or competes with SEI Investments, Demant AS, Coca Cola, Golub Capital, First Trust, Oric Pharmaceuticals, and Blueone Card. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide More
Pfizer Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pfizer's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pfizer Inc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.44 | |||
| Information Ratio | 0.0576 | |||
| Maximum Drawdown | 7.97 | |||
| Value At Risk | (2.24) | |||
| Potential Upside | 2.24 |
Pfizer Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pfizer's standard deviation. In reality, there are many statistical measures that can use Pfizer historical prices to predict the future Pfizer's volatility.| Risk Adjusted Performance | 0.0787 | |||
| Jensen Alpha | 0.087 | |||
| Total Risk Alpha | 0.0332 | |||
| Sortino Ratio | 0.0555 | |||
| Treynor Ratio | 0.1528 |
Pfizer January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0787 | |||
| Market Risk Adjusted Performance | 0.1628 | |||
| Mean Deviation | 1.03 | |||
| Semi Deviation | 1.14 | |||
| Downside Deviation | 1.44 | |||
| Coefficient Of Variation | 981.89 | |||
| Standard Deviation | 1.38 | |||
| Variance | 1.92 | |||
| Information Ratio | 0.0576 | |||
| Jensen Alpha | 0.087 | |||
| Total Risk Alpha | 0.0332 | |||
| Sortino Ratio | 0.0555 | |||
| Treynor Ratio | 0.1528 | |||
| Maximum Drawdown | 7.97 | |||
| Value At Risk | (2.24) | |||
| Potential Upside | 2.24 | |||
| Downside Variance | 2.06 | |||
| Semi Variance | 1.31 | |||
| Expected Short fall | (1.07) | |||
| Skewness | 0.0725 | |||
| Kurtosis | 1.05 |
Pfizer Inc Backtested Returns
At this point, Pfizer is very steady. Pfizer Inc maintains Sharpe Ratio (i.e., Efficiency) of 0.11, which implies the firm had a 0.11 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Pfizer Inc, which you can use to evaluate the volatility of the company. Please check Pfizer's Semi Deviation of 1.14, risk adjusted performance of 0.0787, and Coefficient Of Variation of 981.89 to confirm if the risk estimate we provide is consistent with the expected return of 0.16%. Pfizer has a performance score of 8 on a scale of 0 to 100. The company holds a Beta of 0.86, which implies possible diversification benefits within a given portfolio. Pfizer returns are very sensitive to returns on the market. As the market goes up or down, Pfizer is expected to follow. Pfizer Inc right now holds a risk of 1.43%. Please check Pfizer Inc total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power , to decide if Pfizer Inc will be following its historical price patterns.
Auto-correlation | 0.52 |
Modest predictability
Pfizer Inc has modest predictability. Overlapping area represents the amount of predictability between Pfizer time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pfizer Inc price movement. The serial correlation of 0.52 indicates that about 52.0% of current Pfizer price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.26 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pfizer Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pfizer Inc reported net income of 8.05 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
Pfizer Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in net income category among its peers.
Pfizer ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.Environmental | Governance | Social |
Pfizer Institutional Holders
Institutional Holdings refers to the ownership stake in Pfizer that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pfizer's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pfizer's value.| Shares | Charles Schwab Investment Management Inc | 2025-06-30 | 49.2 M | Fisher Asset Management, Llc | 2025-06-30 | 48.4 M | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 43.9 M | Legal & General Group Plc | 2025-06-30 | 38.4 M | Amundi | 2025-06-30 | 37.4 M | Bank Of New York Mellon Corp | 2025-06-30 | 36 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 34.8 M | Goldman Sachs Group Inc | 2025-06-30 | 30.3 M | Royal Bank Of Canada | 2025-06-30 | 29.5 M | Vanguard Group Inc | 2025-06-30 | 533.4 M | Blackrock Inc | 2025-06-30 | 494.9 M |
Pfizer Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0519 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 196.54 B | ||||
| Shares Outstanding | 5.69 B | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 67.65 % | ||||
| Number Of Shares Shorted | 129.8 M | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 2.34 X | ||||
| Revenue | 63.63 B | ||||
| Gross Profit | 46.97 B | ||||
| EBITDA | 18.13 B | ||||
| Net Income | 8.05 B | ||||
| Cash And Equivalents | 1.04 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 66.99 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 16.32 X | ||||
| Cash Flow From Operations | 12.74 B | ||||
| Short Ratio | 2.70 X | ||||
| Earnings Per Share | 1.72 X | ||||
| Price To Earnings To Growth | 3.77 X | ||||
| Target Price | 28.78 | ||||
| Number Of Employees | 81 K | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 147.03 B | ||||
| Total Asset | 213.4 B | ||||
| Retained Earnings | 116.72 B | ||||
| Working Capital | 7.36 B | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
| Annual Yield | 0.07 % | ||||
| Five Year Return | 3.60 % | ||||
| Net Asset | 213.4 B | ||||
| Last Dividend Paid | 1.7 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Pharmaceuticals sector continue expanding? Could Pfizer diversify its offerings? Factors like these will boost the valuation of Pfizer. Anticipated expansion of Pfizer directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pfizer data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.21) | Dividend Share 1.7 | Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth (0.06) |
Investors evaluate Pfizer Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pfizer's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pfizer's market price to deviate significantly from intrinsic value.
It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pfizer's market price signifies the transaction level at which participants voluntarily complete trades.